Form 4: Galectin Therapeutics Director Kevin D Freeman Buys $27,000 in Company Stock
SEC Form 4
Director Kevin D Freeman recently purchased 10,000 shares of Galectin Therapeutics (GALT) common stock at $2.70 per share.
Summary
- On October 16, 2024, Kevin D Freeman, a director of Galectin Therapeutics Inc. (GALT), purchased 10,000 shares of common stock.
- The purchases were made at a price of $2.70 per share.
- Following the transaction, Freeman directly owns 33,469 shares and indirectly owns 80,000 shares through Freeman Global Holdings LLC and 18,063 shares through an IRA.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. It reflects an insider's confidence in the company, but it's a relatively small transaction.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider transactions are closely monitored by investors as they can provide insights into a company's prospects, as perceived by its leadership.
Stakeholder Impact
- The stock purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 10/16/2024 | Date of stock purchase transaction |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.